Tuesday, January 10, 2017

BIOLINE LAUNCHES THE FULL RANGE OF EPIK™ MIRNA ASSAYS

CINCINNATI, Jan 10 (Bernama-GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the EPIK™ miRNA Select Assays, originally developed for the study of individual microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800 EPIK™ miRNA Select Assays in March 2016 and this has now been increased to include all of the organisms listed on the miRBase release 21, which represents over 27,000 miRNA assays. Recent studies continue to show the clinical value of individual miRNA molecules which are released from tissues and cells. The expression of certain individual miRNA molecules correlates with specific disease conditions making them promising biomarker candidates for the early detection of disease, prognosis and monitoring of treatment in both humans and other organisms.



No comments:

Post a Comment